1. Academic Validation
  2. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes

RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes

  • Biochim Biophys Acta Mol Basis Dis. 2021 Oct 1;1867(10):166186. doi: 10.1016/j.bbadis.2021.166186.
Eun Young Kim 1 Stuart E Dryer 2
Affiliations

Affiliations

  • 1 Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA. Electronic address: ekim8@central.uh.edu.
  • 2 Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA; Department of Biomedical Sciences, University of Houston College of Medicine, Houston, TX 77204, USA. Electronic address: sdryer@uh.edu.
Abstract

The soluble urokinase plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney diseases including primary and recurrent focal and segmental glomerulosclerosis (FSGS), diabetic nephropathy, and acute kidney injuries (AKI). Elevated serum suPAR concentration is a negative prognostic indicator in multiple critical clinical conditions. This study has examined the initial transduction steps used by suPAR in cultured mouse podocytes. We now report that the receptor for advanced glycation end-products (RAGE) co-immunoprecipitates with αV and β3 Integrin subunits, which have been previously shown to initiate suPAR signal transduction at the podocyte cell surface. siRNA knock-down of RAGE attenuated Src phosphorylation evoked by either suPAR or by glycated albumin (AGE-BSA), a prototypical RAGE agonist. suPAR effects on Src phosphorylation were also blocked by the structurally dissimilar RAGE antagonists FPS-ZM1 and azeliragon, as well as by cilengitide, an inhibitor of outside-in signaling through αV-integrins. FPS-ZM1 also blocked Src phosphorylation evoked by AGE-BSA. FPS-ZM1 blocked increases in cell surface TRPC6 abundance, cytosolic Reactive Oxygen Species (ROS) and activation of the small GTPase Rac1 evoked by either suPAR or AGE-BSA. In addition, FPS-ZM1 inhibited Src phosphorylation evoked by serum collected from a patient with recurrent FSGS during a relapse. The magnitude of this inhibition was indistinguishable from the effect produced by a neutralizing antibody against suPAR. These data suggest that orally bioavailable small molecule RAGE antagonists could represent a useful therapeutic strategy for a wide range of clinical conditions associated with elevated serum suPAR, including primary FSGS and AKI.

Keywords

Acute kidney injury; Chronic kidney disease; Focal and segmental glomerulosclerosis; Integrins; RAGE; suPAR.

Figures
Products